Evaluation of gender in the oral pharmacokinetics of clindamycin in humans.
Clindamycin is an antimicrobial agent metabolized by CYP3A4. Gender may influence the pharmacokinetics of drugs metabolized by this pathway, however, no information about differences in the pharmacokinetics of clindamycin in men and women is available. The purpose of this study was to evaluate gender differences in clindamycin oral pharmacokinetics. Twenty-four subjects (11 men and 13 women) received an oral 600 mg dose of clindamycin under fasting conditions and plasma concentrations were obtained at selected times during 12 h. Increased plasma levels were observed in women, but when the dose was normalized by the body weight of individuals, these differences disappeared, indicating that gender does not play an important role in the pharmacokinetics of this drug.
del Carmen Carrasco-Portugal
Miriam
M
Unidad de Farmacología Clínica y Experimental, Instituto Nacional de Enfermedades Respiratorias, Secretaría de Salud, Mexico.
Luján
Miguel
M
Flores-Murrieta
Francisco Javier
FJ
D000284:Administration, Oral; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001835:Body Weight; D002981:Clindamycin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D012737:Sex Factors
D000900:Anti-Bacterial Agents; D002981:Clindamycin; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human